Scholarlink

Background <p>Adenosquamous carcinoma of the pancreas (ASCP) is a rare and aggressive subtype of pancreatic cancer. Compared with other pancreatic tumors, ASCP has a notably poorer prognosis and shorter survival rates. The optimal therapeutic approaches to ASCP have yet to be defined.</p> Methods <p>This retrospective, multicenter European study included all consecutive patients who underwent elective pancreatic surgery for ASCP at participating centers between 2010 and 2024. The inclusion criteria encompassed all patients who underwent scheduled surgery for ASCP during the study period. The exclusion criteria ruled out patients without a confirmed pathologic diagnosis of ASCP, those who did not undergo surgery, and patients with extra-pancreatic disease.</p> Results <p>The study analyzed 194 patients from 29 hospitals in 11 European countries. The overall survival rates were 56.2% at 1 year, 26.3% at 3 years, and 9.8% at 5 years. The disease-free survival rates at the same intervals were 36.6%, 16.5%, and 6.7%, respectively. In the multivariate analysis, significant associations with shorter survival were R2 resections, lymphatic stromal invasion, T4 stage, no adjuvant chemotherapy, and recurrence.</p> Conclusions <p>Patients who undergo resection for ASCP experience very low 5-year survival rates (10%). It is advisable to avoid resecting T4 tumors in patients with significant comorbidities or R2 resections. Additionally, failure to provide adjuvant chemotherapy, often due to severe postoperative complications, further deteriorates the prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adenosquamous Carcinoma of the Pancreas: Outcomes of a Multicenter European Study (ADESQUPAN Project)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Jose Manuel Ramia,
  • Celia Villodre,
  • Dimitrios Giakoustidis,
  • Paraskevi Chatzikomnitsa,
  • Pietro Addeo,
  • Philippe Bachellier,
  • Gennaro Nappo,
  • Alessandro Zerbi,
  • Julie Navez,
  • Gerardo Blanco-Fernández,
  • Jakob Kirkegård,
  • Juli Busquets,
  • Bergthor Björnsson,
  • Santiago Sánchez-Cabús,
  • Elizabeth Pando,
  • Sebastian Manuel Staubli,
  • Sanjay Pandanaboyana,
  • Daniel Aparicio-López,
  • Harry V. M. Spiers,
  • Paola Melgar,
  • Rami Rhaiem,
  • Maria João Amaral,
  • Cristina Vallejo-Bernad,
  • Bodil Andersson,
  • Fernando Burdío,
  • George Tzimas,
  • Isabel Mora-Oliver,
  • Michael Rousek,
  • Carlos Domingo-del-Pozo,
  • Ahmad Mahamid,
  • Dimitrios Lytras,
  • Evangelos D. Lolis,
  • Rafael López-Andújar,
  • María Sorribas,
  • Pablo Alejandro López,
  • Hassan Elghonemy,
  • Bhargava Chikkala,
  • Weiboom Lim,
  • Anita Balakrishnan,
  • María Villamonte Román,
  • Cristina Ballester,
  • Carlos Hörndler-Algárate,
  • Mario Serradilla-Martín

摘要

Background

Adenosquamous carcinoma of the pancreas (ASCP) is a rare and aggressive subtype of pancreatic cancer. Compared with other pancreatic tumors, ASCP has a notably poorer prognosis and shorter survival rates. The optimal therapeutic approaches to ASCP have yet to be defined.

Methods

This retrospective, multicenter European study included all consecutive patients who underwent elective pancreatic surgery for ASCP at participating centers between 2010 and 2024. The inclusion criteria encompassed all patients who underwent scheduled surgery for ASCP during the study period. The exclusion criteria ruled out patients without a confirmed pathologic diagnosis of ASCP, those who did not undergo surgery, and patients with extra-pancreatic disease.

Results

The study analyzed 194 patients from 29 hospitals in 11 European countries. The overall survival rates were 56.2% at 1 year, 26.3% at 3 years, and 9.8% at 5 years. The disease-free survival rates at the same intervals were 36.6%, 16.5%, and 6.7%, respectively. In the multivariate analysis, significant associations with shorter survival were R2 resections, lymphatic stromal invasion, T4 stage, no adjuvant chemotherapy, and recurrence.

Conclusions

Patients who undergo resection for ASCP experience very low 5-year survival rates (10%). It is advisable to avoid resecting T4 tumors in patients with significant comorbidities or R2 resections. Additionally, failure to provide adjuvant chemotherapy, often due to severe postoperative complications, further deteriorates the prognosis.